8-K Announcements
6Material company update
Feb 13, 2026·SEC
Material company update
Nov 26, 2025·SEC
Material company update
May 9, 2025·SEC
Actinium Pharmaceuticals, Inc.(ATNM)Earnings, Financials & Key Ratios
ATNM•AMEX
Price updated Jun 19, 2026
AboutActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.Show more
- Revenue$90K
- EBITDA-$35M+14.2%
- Net Income-$34M+11.4%
- EPS (Diluted)-1.09+14.2%
- Gross Margin100%
- EBITDA Margin-39362.22%
- Operating Margin-40274.44%
- Net Margin-37652.22%
- ROE-166.96%-50.9%
ATNM Key Insights
Actinium Pharmaceuticals, Inc. (ATNM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ATNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATNM Price & Volume
Actinium Pharmaceuticals, Inc. (ATNM) stock price & volume — 10-year historical chart
Loading chart...
ATNM Growth Metrics
Actinium Pharmaceuticals, Inc. (ATNM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-55.63%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.98%
Return on Capital
10 Years-113.14%
5 Years-51.63%
3 Years-60.89%
Last Year-64.41%
ATNM Recent Earnings
Actinium Pharmaceuticals, Inc. (ATNM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.18+18.2%
$0.22
Rev
—
$3M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.19-1.8%
$0.19
Rev
—
$600,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.16+36.0%
$0.25
Rev
$90,000+33.3%
$67,500
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.22+31.3%
$0.32
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.18vs $0.22+18.2% | —vs $3M |
| Q2 2026 | Mar 30, 2026 | $0.19vs $0.19-1.8% | —vs $600,000 |
| Q4 2025 | Nov 14, 2025 | $0.16vs $0.25+36.0% | $90,000vs $67,500+33.3% |
| Q3 2025 | Aug 8, 2025 | $0.22vs $0.32+31.3% | — |
Based on last 12 quarters of dataView full earnings history →
ATNM Peer Comparison
Actinium Pharmaceuticals, Inc. (ATNM) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RNAC | 282.94M | 9.63 | -1.92 | -92.81% | -85.51% | |||
 RAIN | 16.75M | 2.06 | -1.72 | -901.82% | ||||
 PHAT | 864.2M | 10.88 | -3.59 | 216.93% | -61.95% | |||
 NVX | 114.02M | 0.53 | -0.88 | -51.75% | -8.76% | -81.63% | 0.51 | |
 RNW | 2.3B | 6.32 | 20.01 | 43.31% | 7.82% | 7.42% | 5.40 | |
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 |
Compare ATNM vs Peers
Actinium Pharmaceuticals, Inc. (ATNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATNM Income Statement
Actinium Pharmaceuticals, Inc. (ATNM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 1.14M | 1.03M | 81K | 0 | 90K | 90K |
Revenue Growth % | - | - | - | - | - | -9.96% | -92.14% | -100% | - | - |
Cost of Goods Sold | 55.94K | 50.72K | 420.09K | 447K | 524K | 0 | 0 | 811K | 0 | -395K |
COGS % of Revenue | - | - | - | - | 45.8% | - | - | - | - | - |
Gross Profit | -55.94K▲ 0% | -50.72K▲ 9.3% | -420.09K▼ 728.2% | -447K▼ 6.4% | 620K▲ 238.7% | 1.03M▲ 66.1% | 81K▼ 92.1% | -811K▼ 1101.2% | 90K▲ 111.1% | 485K▲ 0% |
Gross Margin % | - | - | - | - | 54.2% | 100% | 100% | - | 100% | 538.89% |
Gross Profit Growth % | 27.84% | 9.33% | -728.23% | -6.41% | 238.7% | 66.13% | -92.14% | -1101.23% | 111.1% | - |
Operating Expenses | 26.91M | 23.83M | 21.65M | 21.95M | 25.58M | 35.13M | 52M | 41.31M | 36.34M | 26M |
OpEx % of Revenue | - | - | - | - | 2236.36% | 3411.07% | 64198.77% | - | 40374.44% | - |
Selling, General & Admin | 9.15M | 6.73M | 5.1M | 6.31M | 8.08M | 12M | 13.33M | 12.08M | 15.21M | 7.98M |
SG&A % of Revenue | - | - | - | - | 706.03% | 1164.95% | 16458.02% | - | 16903.33% | - |
Research & Development | 17.7M | 17.09M | 16.55M | 16.09M | 17.51M | 23.14M | 38.67M | 30.05M | 21.12M | 18.24M |
R&D % of Revenue | - | - | - | - | 1530.33% | 2246.12% | 47740.74% | - | 23471.11% | - |
Other Operating Expenses | 55.94K | 0 | 0 | -447K | 0 | 0 | 0 | -811K | 0 | -220K |
Operating Income | -26.91M▲ 0% | -23.83M▲ 11.5% | -22.07M▲ 7.4% | -22.39M▼ 1.5% | -24.96M▼ 11.5% | -34.1M▼ 36.6% | -51.92M▼ 52.2% | -42.12M▲ 18.9% | -36.25M▲ 13.9% | -25.51M▲ 0% |
Operating Margin % | - | - | - | - | -2182.17% | -3311.07% | -64098.77% | - | -40274.44% | -28346.67% |
Operating Income Growth % | -0.24% | 11.46% | 7.37% | -1.46% | -11.48% | -36.61% | -52.24% | 18.87% | 13.95% | - |
EBITDA | -26.86M | -23.78M | -21.65M | -21.95M | -24.44M | -33.41M | -51.13M | -41.31M | -35.43M | -24.68M |
EBITDA Margin % | - | - | - | - | -2136.36% | -3243.2% | -63123.46% | - | -39362.22% | -27417.78% |
EBITDA Growth % | -0.32% | 11.46% | 8.94% | -1.36% | -11.36% | -36.68% | -53.06% | 19.21% | 14.24% | 48.98% |
D&A (Non-Cash Add-back) | 55.94K | 50.72K | 420.09K | 447K | 524K | 699K | 790K | 811K | 821K | 836K |
EBIT | -26.91M | -23.83M | -21.9M | -22.21M | -24.77M | -34.1M | -51.92M | -38.24M | -36.25M | -25.51M |
Net Interest Income | 0 | 0 | 0 | 178K | 190K | 1.09M | 3.1M | 3.88M | 2.36M | -319K |
Interest Income | 5.43K | 173.36K | 172.39K | 178K | 190K | 1.09M | 3.1M | 3.88M | 2.36M | -319K |
Interest Expense | 5.43K | 173.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 309.55K | 173.36K | 172.39K | 178K | 190K | 1.09M | 3.1M | 3.88M | 2.36M | 2.04M |
Pretax Income | -26.6M▲ 0% | -23.65M▲ 11.1% | -21.9M▲ 7.4% | -22.21M▼ 1.4% | -24.77M▼ 11.5% | -33.02M▼ 33.3% | -48.82M▼ 47.9% | -38.24M▲ 21.7% | -33.89M▲ 11.4% | -23.47M▲ 0% |
Pretax Margin % | - | - | - | - | -2165.56% | -3205.53% | -60269.14% | - | -37652.22% | -26078.89% |
Income Tax | 0 | 173.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -0.73% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -26.6M▲ 0% | -23.65M▲ 11.1% | -21.9M▲ 7.4% | -22.21M▼ 1.4% | -24.77M▼ 11.5% | -33.02M▼ 33.3% | -48.82M▼ 47.9% | -38.24M▲ 21.7% | -33.89M▲ 11.4% | -23.47M▲ 0% |
Net Margin % | - | - | - | - | -2165.56% | -3205.53% | -60269.14% | - | -37652.22% | -26078.89% |
Net Income Growth % | -9.37% | 11.08% | 7.42% | -1.44% | -11.52% | -33.27% | -47.86% | 21.66% | 11.39% | 48.43% |
Net Income (Continuing) | -26.6M | -23.65M | -21.9M | -22.21M | -24.77M | -33.02M | -48.82M | -38.24M | -33.89M | -23.47M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -11.96▲ 0% | -6.69▲ 44.1% | -4.37▲ 34.7% | -1.83▲ 58.1% | -1.20▲ 34.4% | -1.37▼ 14.2% | -1.83▼ 33.6% | -1.27▲ 30.6% | -1.09▲ 14.2% | -0.75▲ 0% |
EPS Growth % | 20.58% | 44.06% | 34.68% | 58.12% | 34.43% | -14.17% | -33.58% | 30.6% | 14.17% | 48.98% |
EPS (Basic) | -11.96 | -6.69 | -4.37 | -1.83 | -1.20 | -1.37 | -1.83 | -1.27 | -1.09 | - |
Diluted Shares Outstanding | 2.23M | 3.54M | 4.98M | 12.13M | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M | 31.24M |
Basic Shares Outstanding | 2.23M | 3.54M | 4.98M | 12.13M | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M | 31.24M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ATNM Balance Sheet
Actinium Pharmaceuticals, Inc. (ATNM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.84M | 14.33M | 10.09M | 64.92M | 79.75M | 110.94M | 78.26M | 74.51M | 49.38M | 43.26M |
Cash & Short-Term Investments | 17.4M | 13.67M | 9.25M | 63.61M | 77.83M | 108.91M | 76.68M | 72.9M | 48M | 42.13M |
Cash Only | 17.4M | 13.67M | 9.25M | 63.61M | 77.83M | 108.91M | 76.68M | 72.9M | 48M | 42.13M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 40.08K | 117.93K | 68K | 442K | 396K | 226K | 357K | 1.38M | 1.13M |
Total Non-Current Assets | 498.15K | 559.79K | 1.58M | 1.47M | 639K | 3.25M | 3.18M | 2.39M | 2.39M | 2.18M |
Property, Plant & Equipment | 57.35K | 118.8K | 1.14M | 1.03M | 639K | 2.95M | 2.87M | 2.07M | 2.06M | 1.84M |
Fixed Asset Turnover | - | - | - | - | 1.79x | 0.35x | 0.03x | - | 0.04x | 0.05x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 49.86K | 49.86K | 391.33K | 391K | 0 | 0 | 313K | 324K | 0 | 998K |
Other Non-Current Assets | 390.94K | 391.13K | 49.86K | 50K | 0 | 302K | 0 | 0 | 335K | 0 |
Total Assets | 18.34M▲ 0% | 14.89M▼ 18.8% | 11.67M▼ 21.6% | 66.4M▲ 468.9% | 80.39M▲ 21.1% | 114.19M▲ 42.1% | 81.44M▼ 28.7% | 76.9M▼ 5.6% | 51.77M▼ 32.7% | 45.44M▲ 0% |
Asset Turnover | - | - | - | - | 0.01x | 0.01x | 0.00x | - | 0.00x | 0.00x |
Asset Growth % | -18.61% | -18.8% | -21.62% | 468.93% | 21.07% | 42.05% | -28.68% | -5.58% | -32.67% | -127.97% |
Total Current Liabilities | 4.67M | 6.06M | 5.34M | 4.77M | 6.84M | 10.63M | 8.49M | 8.15M | 7.97M | 7.35M |
Accounts Payable | 4.65M | 5.81M | 4.6M | 4.34M | 5.54M | 10.13M | 7.95M | 7.57M | 0 | 6.62M |
Days Payables Outstanding | 30.34K | 41.84K | 4K | 3.54K | 3.86K | - | - | 3.41K | - | -4.75K |
Short-Term Debt | 0 | 249.24K | 381K | 427K | 0 | 0 | 541K | 0 | 722K | 734K |
Deferred Revenue (Current) | 0 | -6.06M | -4.6M | 0 | 0 | 0 | 0 | 0 | 35M | 70M |
Other Current Liabilities | 15.92K | 0 | 4.6M | 0 | 998K | 0 | 0 | 0 | -27.75M | 0 |
Current Ratio | 3.82x | 2.36x | 1.89x | 13.62x | 11.66x | 10.44x | 9.21x | 9.14x | 6.20x | 5.89x |
Quick Ratio | 3.82x | 2.36x | 1.89x | 13.62x | 11.66x | 10.44x | 9.21x | 9.14x | 6.20x | 5.89x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 13.35K | 682.31K | 311K | 3K | 37.08M | 36.57M | 35.99M | 35.97M | 35.78M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 13.35K | 682K | 311K | 3K | 2.08M | 1.57M | 993K | 972K | 2.98M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 311 | 0 | 0 | 35M | 0 | 0 | 0 | 0 |
Total Liabilities | 4.67M | 6.08M | 6.03M | 5.08M | 6.84M | 47.71M | 45.07M | 44.14M | 43.94M | 43.13M |
Total Debt | 0 | 262.59K | 1.43M | 738K | 310K | 2.58M | 2.11M | 1.57M | 1.69M | 1.52M |
Net Debt | -17.4M | -13.41M | -7.83M | -62.87M | -77.52M | -106.33M | -74.56M | -71.33M | -46.3M | -40.61M |
Debt / Equity | - | 0.03x | 0.25x | 0.01x | 0.00x | 0.04x | 0.06x | 0.05x | 0.22x | 0.66x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.65x |
Interest Coverage | -4955.99x | -137.44x | - | - | - | - | - | - | - | - |
Total Equity | 13.67M▲ 0% | 8.81M▼ 35.5% | 5.64M▼ 36.0% | 61.32M▲ 986.4% | 73.55M▲ 19.9% | 66.48M▼ 9.6% | 36.38M▼ 45.3% | 32.76M▼ 10.0% | 7.83M▼ 76.1% | 2.3M▲ 0% |
Equity Growth % | -24.08% | -35.54% | -35.95% | 986.36% | 19.94% | -9.61% | -45.28% | -9.95% | -76.09% | -287.67% |
Book Value per Share | 6.14 | 2.49 | 1.13 | 5.05 | 3.58 | 2.75 | 1.37 | 1.09 | 0.25 | 0.07 |
Total Shareholders' Equity | 13.67M | 8.81M | 5.64M | 61.32M | 73.55M | 66.48M | 36.38M | 32.76M | 7.83M | 2.3M |
Common Stock | 80.07K | 115.7K | 164.7K | 18K | 22K | 26K | 28K | 31K | 31K | 31K |
Retained Earnings | -163.15M | -186.86M | -208.76M | -230.97M | -255.75M | -288.76M | -337.58M | -375.83M | -409.71M | -415.24M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -215.66K | -266.38K | 0 | 0 | 0 | 0 | 0 | 0 | -20K | -39K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATNM Cash Flow Statement
Actinium Pharmaceuticals, Inc. (ATNM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -21.55M | -20.57M | -21.46M | -21.62M | -20.87M | 8.64M | -47.34M | -33.07M | -24.58M | -22.88M |
Operating CF Margin % | - | - | - | - | -1823.95% | 839.22% | -58438.27% | - | -27311.11% | - |
Operating CF Growth % | -3.68% | 4.56% | -4.33% | -0.72% | 3.47% | 141.43% | -647.61% | 30.13% | 25.68% | 110.08% |
Net Income | -26.6M | -23.65M | -21.9M | -22.21M | -24.77M | -33.02M | -48.82M | -38.24M | -33.89M | -23.47M |
Depreciation & Amortization | 55.94K | 50.72K | 420.09K | 447K | 524K | 699K | 790K | 811K | 821K | 836K |
Stock-Based Compensation | 3.49M | 1.8M | 1.29M | 1.25M | 1.69M | 2.79M | 3.84M | 5.29M | 9.19M | 316K |
Deferred Taxes | 0 | 0 | -3.39M | -2.4M | -1.55M | 402K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -304.12K | 766.6K | 3.39M | 2.4M | 1.55M | -402K | 0 | 0 | 0 | 11K |
Working Capital Changes | 1.8M | 1.23M | -1.28M | -1.1M | 1.69M | 38.17M | -3.15M | -932K | -704K | -568K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 405.21K | 1.13M | -1.26M | -257K | 1.2M | 4.59M | -2.18M | -387K | -346K | 40K |
Cash from Investing | -380.95K | -96.09K | -63.89K | -253K | -133K | -366K | -153K | -11K | -104K | -106K |
Capital Expenditures | -24.74K | -96.09K | -63.89K | -253K | -133K | -366K | -153K | -11K | -104K | -106K |
CapEx % of Revenue | - | - | - | - | 11.63% | 35.53% | 188.89% | - | 115.56% | 117.78% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -356.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 18.81M | 16.98M | 17.11M | 76.18M | 35.22M | 23.11M | 14.87M | 29.32M | -217K | -218K |
Debt Issued (Net) | 0 | 0 | -322K | -460K | -85K | -49K | -4K | -9K | -10K | -11K |
Equity Issued (Net) | 18.81M | 16.98M | 15.93M | 76.59M | 35.3M | 23.16M | 14.87M | 29.25M | 0 | 0 |
Dividends Paid | 0 | 0 | -1.27K | -1K | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 4.85K | 1.51M | 48K | 6K | 0 | 0 | 75K | -207K | -207K |
Net Change in Cash | -3.12M▲ 0% | -3.69M▼ 18.2% | -4.41M▼ 19.7% | 54.31M▲ 1331.1% | 14.22M▼ 73.8% | 31.39M▲ 120.7% | -32.63M▼ 204.0% | -3.76M▲ 88.5% | -24.89M▼ 561.7% | -23.19M▲ 0% |
Free Cash Flow | -21.58M▲ 0% | -20.67M▲ 4.2% | -21.53M▼ 4.2% | -21.87M▼ 1.6% | -21M▲ 4.0% | 8.28M▲ 139.4% | -47.49M▼ 673.7% | -33.08M▲ 30.3% | -24.68M▲ 25.4% | -22.98M▲ 0% |
FCF Margin % | - | - | - | - | -1835.58% | 803.69% | -58627.16% | - | -27426.67% | -25535.56% |
FCF Growth % | -3.5% | 4.22% | -4.15% | -1.6% | 3.98% | 139.42% | -673.67% | 30.33% | 25.39% | 30.93% |
FCF per Share | -9.70 | -5.85 | -4.33 | -1.80 | -1.02 | 0.34 | -1.78 | -1.10 | -0.79 | -0.74 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.87x | 0.98x | 0.97x | 0.84x | -0.26x | 0.97x | 0.86x | 0.73x | 0.98x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATNM Key Ratios
Actinium Pharmaceuticals, Inc. (ATNM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -167.94% | -210.41% | -302.95% | -66.35% | -36.74% | -47.16% | -94.92% | -110.63% | -166.96% | -218.67% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 49.42% |
Gross Margin | - | - | - | - | 54.2% | 100% | 100% | - | 100% | 538.89% |
Net Margin | - | - | - | - | -2165.56% | -3205.53% | -60269.14% | - | -37652.22% | -26078.89% |
Debt / Equity | - | 0.03x | 0.25x | 0.01x | 0.00x | 0.04x | 0.06x | 0.05x | 0.22x | 0.66x |
Interest Coverage | -4955.99x | -137.44x | - | - | - | - | - | - | - | - |
FCF Conversion | 0.81x | 0.87x | 0.98x | 0.97x | 0.84x | -0.26x | 0.97x | 0.86x | 0.73x | 0.98x |
Revenue Growth | - | - | - | - | - | -9.96% | -92.14% | -100% | - | - |
Related:ATNM Dividend History·ATNM Revenue History·ATNM Price History·ATNM P/E History·ATNM Financial Ratios·ATNM Institutional Holders
ATNM SEC Filings & Documents
Actinium Pharmaceuticals, Inc. (ATNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
ATNM Frequently Asked Questions
Actinium Pharmaceuticals, Inc. (ATNM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Actinium Pharmaceuticals, Inc. (ATNM) reported $0.1M in revenue for fiscal year 2025.
Actinium Pharmaceuticals, Inc. (ATNM) grew revenue by 0.0% over the past year. Growth has been modest.
Actinium Pharmaceuticals, Inc. (ATNM) reported a net loss of $23.5M for fiscal year 2025.
Dividend & Returns
Actinium Pharmaceuticals, Inc. (ATNM) has a return on equity (ROE) of -167.0%. Negative ROE indicates the company is unprofitable.
Actinium Pharmaceuticals, Inc. (ATNM) had negative free cash flow of $23.0M in fiscal year 2025, likely due to heavy capital investments.